Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 10/20 | 0.50 |
| ▸ | PRMT1 | Q99873 | 9/20 | 0.50 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469468 | 0.87 | CARM1 (0.52) | CARM1PRMT1HTR2ASGMS2BCHE | |
| SCHEMBL26811444 | 0.81 | HTR2A (0.62) | HTR2ASGMS2MAPTMAPK1TDP1 | |
| SCHEMBL26660928 | 0.77 | HTR2A (0.48) | HTR2ASGMS2 | |
| SCHEMBL16119991 | 0.77 | TRPM8 (0.48) | CARM1PRMT1PRMT6PRMT8MAPT | |
| SCHEMBL26811912 | 0.76 | HTR2A (0.48) | CARM1PRMT1HTR2ASGMS2BCHE | |
| SCHEMBL26811483 | 0.74 | SGMS2 (0.51) | HTR2ASGMS2MAPTMAPK1TDP1 | |
| SCHEMBL2004850 | 0.74 | SGMS2 (0.55) | HTR2ASGMS2MAPTMAPK1TDP1 | |
| SCHEMBL21266902 | 0.74 | SGMS2 (0.55) | HTR2ASGMS2MAPTMAPK1TDP1 | |
| SCHEMBL30664081 | 0.72 | HTR2A (0.44) | HTR2ASGMS2L3MBTL1 | |
| SCHEMBL17469491 | 0.69 | CARM1 (0.37) | CARM1PRMT1PRMT6PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105497-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2018-04-19 | — | — | US | disclosed |
| US-9943504-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9765035-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170119735-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20160024017-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-01-28 | — | — | US | disclosed |
| US-20140288124-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288124-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | CARM1 12/4885PRMT1 1/4885HTR2A 4184/4885 |
| US-20160024017-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | CARM1 12/4885PRMT1 1/4885HTR2A 4184/4885 |
| US-20170119735-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | CARM1 12/4885PRMT1 1/4885HTR2A 4184/4885 |
| US-20180105497-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | CARM1 12/4885PRMT1 1/4885HTR2A 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.